JP2004517853A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004517853A5 JP2004517853A5 JP2002554050A JP2002554050A JP2004517853A5 JP 2004517853 A5 JP2004517853 A5 JP 2004517853A5 JP 2002554050 A JP2002554050 A JP 2002554050A JP 2002554050 A JP2002554050 A JP 2002554050A JP 2004517853 A5 JP2004517853 A5 JP 2004517853A5
- Authority
- JP
- Japan
- Prior art keywords
- phenyl
- methyl
- methylsulfonyl
- pharmaceutical composition
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 23
- 150000003839 salts Chemical class 0.000 claims 21
- 229940111134 coxibs Drugs 0.000 claims 17
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 17
- 108010047852 Integrin alphaVbeta3 Proteins 0.000 claims 13
- 239000002464 receptor antagonist Substances 0.000 claims 13
- 229940044551 receptor antagonist Drugs 0.000 claims 13
- -1 4- (methylsulfonyl) phenyl Chemical group 0.000 claims 8
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 claims 7
- RZJQGNCSTQAWON-UHFFFAOYSA-N rofecoxib Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=CC=CC=2)C(=O)OC1 RZJQGNCSTQAWON-UHFFFAOYSA-N 0.000 claims 7
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- FZYAFLPJDVKKQI-KRWDZBQOSA-N (5s)-5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CC[C@]1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 FZYAFLPJDVKKQI-KRWDZBQOSA-N 0.000 claims 5
- MNJVRJDLRVPLFE-UHFFFAOYSA-N etoricoxib Chemical compound C1=NC(C)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 MNJVRJDLRVPLFE-UHFFFAOYSA-N 0.000 claims 5
- TZRHLKRLEZJVIJ-UHFFFAOYSA-N parecoxib Chemical compound C1=CC(S(=O)(=O)NC(=O)CC)=CC=C1C1=C(C)ON=C1C1=CC=CC=C1 TZRHLKRLEZJVIJ-UHFFFAOYSA-N 0.000 claims 5
- LNPDTQAFDNKSHK-UHFFFAOYSA-N valdecoxib Chemical compound CC=1ON=C(C=2C=CC=CC=2)C=1C1=CC=C(S(N)(=O)=O)C=C1 LNPDTQAFDNKSHK-UHFFFAOYSA-N 0.000 claims 5
- YICWVYSPJDTUBI-IBGZPJMESA-N (2s)-2-pyrimidin-5-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1([C@H](CCCCCCCC=2N=C3NCCCC3=CC=2)C(=O)O)=CN=CN=C1 YICWVYSPJDTUBI-IBGZPJMESA-N 0.000 claims 4
- 208000002679 Alveolar Bone Loss Diseases 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000028169 periodontal disease Diseases 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- SQHBOFQKSIBJAM-FQEVSTJZSA-N (2s)-2-(2-methylpyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=NC(C)=NC=C1[C@@H](C(O)=O)CCCCCCCC1=CC=C(CCCN2)C2=N1 SQHBOFQKSIBJAM-FQEVSTJZSA-N 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- 102000010907 Cyclooxygenase 2 Human genes 0.000 claims 2
- 108010037462 Cyclooxygenase 2 Proteins 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 229910052736 halogen Inorganic materials 0.000 claims 2
- 150000002367 halogens Chemical class 0.000 claims 2
- FBUKVWPVBMHYJY-UHFFFAOYSA-N nonanoic acid Chemical compound CCCCCCCCC(O)=O FBUKVWPVBMHYJY-UHFFFAOYSA-N 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 125000003652 trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 claims 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- SKSCYVSLPPEPOB-IBGZPJMESA-N (2S)-2-(2-methoxypyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound COc1ncc(cn1)[C@H](CCCCCCCc1ccc2CCCNc2n1)C(O)=O SKSCYVSLPPEPOB-IBGZPJMESA-N 0.000 claims 1
- ZFRPDDKGHCDPNI-OAQYLSRUSA-N (2s)-2-(2,3-dihydro-1-benzofuran-6-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=C2CCOC2=CC([C@@H](CN2C(N(CCCC=3N=C4NCCCC4=CC=3)CC2)=O)C(=O)O)=C1 ZFRPDDKGHCDPNI-OAQYLSRUSA-N 0.000 claims 1
- WFGDRRYHDBVFAY-HXUWFJFHSA-N (2s)-2-(4-ethoxy-3-fluorophenyl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=C(F)C(OCC)=CC=C1[C@H](C(O)=O)CN1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 WFGDRRYHDBVFAY-HXUWFJFHSA-N 0.000 claims 1
- COHQTPRYVPREMW-HXUWFJFHSA-N (2s)-2-(6-ethoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OCC)=CC=C1[C@H](C(O)=O)CN1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 COHQTPRYVPREMW-HXUWFJFHSA-N 0.000 claims 1
- VMECIHUPKIKOEW-LJQANCHMSA-N (2s)-2-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OC)=CC=C1[C@H](C(O)=O)CN1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 VMECIHUPKIKOEW-LJQANCHMSA-N 0.000 claims 1
- YHEYEOGCIDCGAJ-QHCPKHFHSA-N (2s)-2-quinolin-3-yl-9-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)nonanoic acid Chemical compound C1=CC=CC2=CC([C@H](CCCCCCCC=3N=C4NCCCC4=CC=3)C(=O)O)=CN=C21 YHEYEOGCIDCGAJ-QHCPKHFHSA-N 0.000 claims 1
- IEYOLYRZESWODM-JOCHJYFZSA-N (2s)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]-2-quinolin-3-ylpropanoic acid Chemical compound C1=CC=CC2=CC([C@@H](CN3C(N(CCCC=4N=C5NCCCC5=CC=4)CC3)=O)C(=O)O)=CN=C21 IEYOLYRZESWODM-JOCHJYFZSA-N 0.000 claims 1
- XJXCVNTUWJYXTM-OAQYLSRUSA-N (5r)-3-(3-chloro-4-methoxyphenoxy)-5-ethyl-5-methyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound O([C@](C=1C=2C=CC(=CC=2)S(C)(=O)=O)(C)CC)C(=O)C=1OC1=CC=C(OC)C(Cl)=C1 XJXCVNTUWJYXTM-OAQYLSRUSA-N 0.000 claims 1
- XCNHDBDVIVAJHX-UHFFFAOYSA-N 3-(5-bromopyridin-2-yl)oxy-5,5-dimethyl-4-(4-methylsulfonylphenyl)furan-2-one Chemical compound C=1C=C(S(C)(=O)=O)C=CC=1C=1C(C)(C)OC(=O)C=1OC1=CC=C(Br)C=N1 XCNHDBDVIVAJHX-UHFFFAOYSA-N 0.000 claims 1
- HGFOOLONGOBCMP-UHFFFAOYSA-N 3-(6-methoxypyridin-3-yl)-3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)propyl]imidazolidin-1-yl]propanoic acid Chemical compound C1=NC(OC)=CC=C1C(CC(O)=O)N1C(=O)N(CCCC=2N=C3NCCCC3=CC=2)CC1 HGFOOLONGOBCMP-UHFFFAOYSA-N 0.000 claims 1
- INRQTVDUZFESAO-UHFFFAOYSA-N 4-(3,4-difluorophenyl)-3-(4-methylsulfonylphenyl)-2h-furan-5-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=C(F)C(F)=CC=2)C(=O)OC1 INRQTVDUZFESAO-UHFFFAOYSA-N 0.000 claims 1
- KZNGNTKISMAXAG-UHFFFAOYSA-N 4-(3-fluorophenyl)-3-(4-methylsulfonylphenyl)-2h-furan-5-one Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=C(C=2C=C(F)C=CC=2)C(=O)OC1 KZNGNTKISMAXAG-UHFFFAOYSA-N 0.000 claims 1
- LQDZIMSKYUVVHN-UHFFFAOYSA-N 4-[4-(3,4-dichlorophenyl)-5-oxo-2h-furan-3-yl]benzenesulfonamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=C(C=2C=C(Cl)C(Cl)=CC=2)C(=O)OC1 LQDZIMSKYUVVHN-UHFFFAOYSA-N 0.000 claims 1
- KEHWUUBPFIVOBI-UHFFFAOYSA-N 4-[4-(3-chloro-4-methoxyphenyl)-5-oxo-2h-furan-3-yl]benzenesulfonamide Chemical compound C1=C(Cl)C(OC)=CC=C1C1=C(C=2C=CC(=CC=2)S(N)(=O)=O)COC1=O KEHWUUBPFIVOBI-UHFFFAOYSA-N 0.000 claims 1
- ONJHHYBWKLDIFI-UHFFFAOYSA-N 5,5-dimethyl-4-(4-methylsulfonylphenyl)-3-propan-2-yloxyfuran-2-one Chemical compound CC1(C)OC(=O)C(OC(C)C)=C1C1=CC=C(S(C)(=O)=O)C=C1 ONJHHYBWKLDIFI-UHFFFAOYSA-N 0.000 claims 1
- WRQFOMMHNDHSPD-UHFFFAOYSA-N 5-chloro-2-(6-ethylpyridin-3-yl)-3-(4-methylsulfonylphenyl)pyridine Chemical compound C1=NC(CC)=CC=C1C1=NC=C(Cl)C=C1C1=CC=C(S(C)(=O)=O)C=C1 WRQFOMMHNDHSPD-UHFFFAOYSA-N 0.000 claims 1
- CUVUXNULRBGYON-UHFFFAOYSA-N L787257 Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC(Cl)=CN=C1C1=CC=CN=C1 CUVUXNULRBGYON-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000003239 periodontal effect Effects 0.000 claims 1
- 125000002572 propoxy group Chemical group [*]OC([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Claims (28)
3−フェニル−4−(4−(メチルスルホニル)フェニル)−2−(5H)−フラノン、
3−(3−フルオロフェニル)−4−(4−(メチルスルホニル)フェニル)−2−(5H)−フラノン、
3−(3,4−ジフルオロフェニル)−4−(4−(メチルスルホニル)フェニル)−2−(5H)−フラノン、
3−(3,4−トリクロロフェニル)−4−(4−(メチルスルホニル)フェニル)−2−(5H)−フラノン、
3−(3,4−ジクロロフェニル)−4−(4−(アミノスルホニル)フェニル)−2−(5H)−フラノン、
3−(3−クロロ−4−メトキシフェニル)−4−(4−(アミノスルホニル)フェニル)−2−(5H)−フラノン、
4−[5−(4−メチルフェニル)−3−(トリフルオロメチル)−1H−ピラゾール−1−イル]ベンゼンスルホンアミド、
(5S)−5−エチル−5−メチル−4−(4−(メタンスルホニル)フェニル)−3−(2−プロポキシ)−(5H)−フラン−2−オン、
5,5−ジメチル−4−(4−(メチルスルホニル)フェニル)−3−(2−プロポキシ)−5H−フラン−2−オン、
5,5−ジメチル−4−(4−(メチルスルホニル)フェニル)−3−(5−ブロモピリジン−2−イルオキシ)−5H−フラン−2−オン、
5−メチル−4−(4−(メチルスルホニル)フェニル)−3−(2−(プロポキシ)−5−(2−トリフルオロエチル)−5H−フラン−2−オン、
3−(3−トリフルオロメチル)フェノキシ−4−(4−(メチルスルホニル)フェニル)−5,5−ジメチル−5H−フラン−2−オン、
(5R)−3−(3−クロロ−4−メトキシフェノキシ)−5−エチル−5−メチル−4−(4−(メチルスルホニル)フェニル)−5H−フラン−2−オン、
5−クロロ−3−(4−(メチルスルホニル)フェニル)−2−(2−メチル−5−ピリジニル)ピリジン、
5−クロロ−3−(4−(メチルスルホニル)フェニル)−2−(2−エチル−5−ピリジニル)ピリジン、
5−クロロ−3−(4−(メチルスルホニル)フェニル)−2−(3−ピリジニル)ピリジン、
4−(5−メチル−3−フェニル−4−イソオキサゾリル)−ベンゼンスルホンアミド、及び、
N−[[4−(5−メチル−3−フェニル−4−イソオキサゾリル)フェニル]スルホニル]プロパンアミド、
または、医薬的に許容されるそれらの塩からなるグループから選択される、請求項1に記載の医薬組成物。 A COX-2 inhibitor
3-phenyl-4- (4- (methylsulfonyl) phenyl) -2- (5H) -furanone,
3- (3-fluorophenyl) -4- (4- (methylsulfonyl) phenyl) -2- (5H) -furanone,
3- (3,4-difluorophenyl) -4- (4- (methylsulfonyl) phenyl) -2- (5H) -furanone,
3- (3,4-trichlorophenyl) -4- (4- (methylsulfonyl) phenyl) -2- (5H) -furanone,
3- (3,4-dichlorophenyl) -4- (4- (aminosulfonyl) phenyl) -2- (5H) -furanone,
3- (3-chloro-4-methoxyphenyl) -4- (4- (aminosulfonyl) phenyl) -2- (5H) -furanone,
4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide,
(5S) -5-ethyl-5-methyl-4- (4- (methanesulfonyl) phenyl) -3- (2-propoxy)-(5H) -furan-2-one,
5,5-dimethyl-4- (4- (methylsulfonyl) phenyl) -3- (2-propoxy) -5H-furan-2-one,
5,5-dimethyl-4- (4- (methylsulfonyl) phenyl) -3- (5-bromopyridin-2-yloxy) -5H-furan-2-one,
5-methyl-4- (4- (methylsulfonyl) phenyl) -3- (2- (propoxy) -5- (2-trifluoroethyl) -5H-furan-2-one,
3- (3-trifluoromethyl) phenoxy-4- (4- (methylsulfonyl) phenyl) -5,5-dimethyl-5H-furan-2-one,
(5R) -3- (3-chloro-4-methoxyphenoxy) -5-ethyl-5-methyl-4- (4- (methylsulfonyl) phenyl) -5H-furan-2-one,
5-chloro-3- (4- (methylsulfonyl) phenyl) -2- (2-methyl-5-pyridinyl) pyridine,
5-chloro-3- (4- (methylsulfonyl) phenyl) -2- (2-ethyl-5-pyridinyl) pyridine,
5-chloro-3- (4- (methylsulfonyl) phenyl) -2- (3-pyridinyl) pyridine,
4- (5-methyl-3-phenyl-4-isoxazolyl) -benzenesulfonamide, and
N-[[4- (5-Methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonyl] propanamide,
Alternatively, the pharmaceutical composition according to claim 1, selected from the group consisting of pharmaceutically acceptable salts thereof .
3−フェニル−4−(4−(メチルスルホニル)フェニル)−2−(5H)−フラノン、
4−[5−(4−メチルフェニル)−3−(トリフルオロメチル)−1H−ピラゾール−1−イル]ベンゼンスルホンアミド、
4−(5−メチル−3−フェニル−4−イソオキサゾリル)−ベンゼンスルホンアミド、
N−[[4−(5−メチル−3−フェニル−4−イソオキサゾリル)フェニル]スルホニル]プロパンアミド、
5−クロロ−3−(4−(メチルスルホニル)フェニル)−2−(2−メチル−5−ピリジニル)ピリジン、及び、
(5S)−5−エチル−5−メチル−4−(4−(メタンスルホニル)フェニル)−3−(2−プロポキシ)−(5H)−フラン−2−オン、
または、医薬的に許容されるそれらの塩からなるグループから選択される、請求項2に記載の医薬組成物。 A COX-2 inhibitor
3-phenyl-4- (4- (methylsulfonyl) phenyl) -2- (5H) -furanone,
4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide,
4- (5-methyl-3-phenyl-4-isoxazolyl) -benzenesulfonamide,
N-[[4- (5-Methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonyl] propanamide,
5-chloro-3- (4- (methylsulfonyl) phenyl) -2- (2-methyl-5-pyridinyl) pyridine, and
(5S) -5-ethyl-5-methyl-4- (4- (methanesulfonyl) phenyl) -3- (2-propoxy)-(5H) -furan-2-one,
Alternatively, the pharmaceutical composition according to claim 2, selected from the group consisting of pharmaceutically acceptable salts thereof .
R2は水素またはC1−4アルキルを表し、
R3はアリールを表し、ここにアリールは、モノ置換またはジ置換の
キノリル、
ピリジニルまたは
ピリミジニル
を表し、
置換基の各々は独立に、水素、ハロゲン、フェニル、C1−4アルキル、C3−6シクロアルキル、C1−3アルコキシ、アミノ、C1−3アルキルアミノ、ジ(C1−3アルキル)アミノ、ヒドロキシ、シアノ、トリフルオロメチル、1,1,1−トリフルオロエチル、トリフルオロメトキシまたはトリフルオロエトキシを表す〕
の化合物である、請求項1に記載の医薬組成物。 The αvβ3 integrin receptor antagonist has the structural formula (VII):
R 2 represents hydrogen or C 1-4 alkyl;
R 3 represents aryl, where aryl is mono- or di-substituted quinolyl,
Represents pyridinyl or pyrimidinyl,
Each of the substituents is independently hydrogen, halogen, phenyl, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, amino, C 1-3 alkylamino, di (C 1-3 alkyl) Represents amino, hydroxy, cyano, trifluoromethyl, 1,1,1-trifluoroethyl, trifluoromethoxy or trifluoroethoxy)
The pharmaceutical composition according to claim 1, wherein
3(S)−(2,3−ジヒドロ−ベンゾフラン−6−イル)−3−{2−オキソ−3−[3−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−プロピル]−イミダゾリジン−1−イル}−プロピオン酸、
3(S)−(6−メトキシピリジン−3−イル)−3−{2−オキソ−3−[3−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−プロピル]−イミダゾリジン−1−イル}−プロピオン酸、
3(S)−(6−エトキシピリジン−3−イル)−3−{2−オキソ−3−[3−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−プロピル]−イミダゾリジン−1−イル}−プロピオン酸、
3(S)−(キノリン−3−イル)−3−{2−オキソ−3−[3−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−プロピル]−イミダゾリジン−1−イル}−プロピオン酸、及び、
3(S)−(4−エトキシ−3−フルオロフェニル)−3−{2−オキソ−3−[3−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−プロピル]−イミダゾリジン−1−イル}−プロピオン酸、
または、医薬的に許容されるそれらの塩からなるグループから選択される、請求項10に記載の医薬組成物。 an αvβ3 integrin receptor antagonist is
3 (S)-(2,3-dihydro-benzofuran-6-yl) -3- {2-oxo-3- [3- (5,6,7,8-tetrahydro- [1,8] -naphthyridine- 2-yl) -propyl] -imidazolidin-1-yl} -propionic acid,
3 (S)-(6-Methoxypyridin-3-yl) -3- {2-oxo-3- [3- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl ) -Propyl] -imidazolidin-1-yl} -propionic acid,
3 (S)-(6-Ethoxypyridin-3-yl) -3- {2-oxo-3- [3- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl ) -Propyl] -imidazolidin-1-yl} -propionic acid,
3 (S)-(Quinolin-3-yl) -3- {2-oxo-3- [3- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -propyl ] -Imidazolidin-1-yl} -propionic acid, and
3 (S)-(4-Ethoxy-3-fluorophenyl) -3- {2-oxo-3- [3- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl ) -Propyl] -imidazolidin-1-yl} -propionic acid,
Alternatively, the pharmaceutical composition according to claim 10, selected from the group consisting of pharmaceutically acceptable salts thereof .
R2は水素またはC1−4アルキルを表し、
R3は、モノ置換またはジ置換の
キノリル、
ピリジニルまたは
ピリミジニル
を表し、
置換基の各々は独立に、水素、ハロゲン、フェニル、C1−4アルキル、C3−6シクロアルキル、C1−3アルコキシ、アミノ、C1−3アルキルアミノ、ジ(C1−3アルキル)アミノ、ヒドロキシ、シアノ、トリフルオロメチル、1,1,1−トリフルオロエチル、トリフルオロメトキシまたはトリフルオロエトキシを表す〕の化合物である、請求項1に記載の医薬組成物。 The αvβ3 integrin receptor antagonist has the structural formula VIII:
R 2 represents hydrogen or C 1-4 alkyl;
R 3 is mono- or di-substituted quinolyl,
Represents pyridinyl or pyrimidinyl,
Each of the substituents is independently hydrogen, halogen, phenyl, C 1-4 alkyl, C 3-6 cycloalkyl, C 1-3 alkoxy, amino, C 1-3 alkylamino, di (C 1-3 alkyl) The pharmaceutical composition according to claim 1, which is a compound of amino, hydroxy, cyano, trifluoromethyl, 1,1,1-trifluoroethyl, trifluoromethoxy or trifluoroethoxy.
3(S)−(2−メトキシ−ピリミジン−5−イル)−9−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−ノナン酸、
3(S)−(ピリミジン−5−イル)−9−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−ノナン酸、
3(S)−(2−メチル−ピリミジン−5−イル)−9−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−ノナン酸、及び、
3(S)−(キノリン−3−イル)−9−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−ノナン酸、
または、医薬的に許容されるそれらの塩からなるグループから選択される、請求項13に記載の医薬組成物。 an αvβ3 integrin receptor antagonist is
3 (S)-(2-methoxy-pyrimidin-5-yl) -9- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -nonanoic acid,
3 (S)-(pyrimidin-5-yl) -9- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -nonanoic acid,
3 (S)-(2-methyl-pyrimidin-5-yl) -9- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -nonanoic acid, and
3 (S)-(quinolin-3-yl) -9- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -nonanoic acid,
Alternatively, the pharmaceutical composition according to claim 13, selected from the group consisting of pharmaceutically acceptable salts thereof .
3−フェニル−4−(4−(メチルスルホニル)フェニル)−2−(5H)−フラノン、
4−[5−(4−メチルフェニル)−3−(トリフルオロメチル)−1H−ピラゾール−1−イル]ベンゼンスルホンアミド、
4−(5−メチル−3−フェニル−4−イソオキサゾリル)−ベンゼンスルホンアミド、
N−[[4−(5−メチル−3−フェニル−4−イソオキサゾリル)フェニル]スルホニル]プロパンアミド、
5−クロロ−3−(4−(メチルスルホニル)フェニル)−2−(2−メチル−5−ピリジニル)ピリジン、及び、
(5S)−5−エチル−5−メチル−4−(4−(メタンスルホニル)フェニル)−3−(2−プロポキシ)−(5H)−フラン−2−オン、
または、医薬的に許容されるそれらの塩からなるグループから選択される、請求項21に記載の医薬組成物。 A COX-2 inhibitor
3-phenyl-4- (4- (methylsulfonyl) phenyl) -2- (5H) -furanone,
4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide,
4- (5-methyl-3-phenyl-4-isoxazolyl) -benzenesulfonamide,
N-[[4- (5-Methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonyl] propanamide,
5-chloro-3- (4- (methylsulfonyl) phenyl) -2- (2-methyl-5-pyridinyl) pyridine, and
(5S) -5-ethyl-5-methyl-4- (4- (methanesulfonyl) phenyl) -3- (2-propoxy)-(5H) -furan-2-one,
Or the pharmaceutical composition according to claim 21, selected from the group consisting of pharmaceutically acceptable salts thereof.
3(S)−(2−メチル−ピリミジン−5−イル)−9−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−ノナン酸、
3(S)−(ピリミジン−5−イル)−9−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−ノナン酸、及び、
3(S)−(2−メトキシピリミジン−5−イル)−3−{2−オキソ−3−[3−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−プロピル]−イミダゾリジン−1−イル}−プロピオン酸、
または、医薬的に許容されるそれらの塩からなるグループから選択される、請求項21に記載の医薬組成物。 an αvβ3 integrin receptor antagonist is
3 (S)-(2-methyl-pyrimidin-5-yl) -9- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -nonanoic acid,
3 (S)-(pyrimidin-5-yl) -9- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -nonanoic acid, and
3 (S)-(2-methoxypyrimidin-5-yl) -3- {2-oxo-3- [3- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl ) -Propyl] -imidazolidin-1-yl} -propionic acid,
Or the pharmaceutical composition according to claim 21, selected from the group consisting of pharmaceutically acceptable salts thereof.
3(S)−(2−メチル−ピリミジン−5−イル)−9−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−ノナン酸、
3(S)−(ピリミジン−5−イル)−9−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−ノナン酸、及び、
3−(6−メトキシピリジン−3−イル)−3−{2−オキソ−3−[3−(5,6,7,8−テトラヒドロ−[1,8]−ナフチリジン−2−イル)−プロピル]−イミダゾリジン−1−イル}−プロピオン酸、
または、医薬的に許容されるそれらの塩からなるグループから選択される、請求項25に記載の使用。 an αvβ3 integrin receptor antagonist is
3 (S)-(2-methyl-pyrimidin-5-yl) -9- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -nonanoic acid,
3 (S)-(pyrimidin-5-yl) -9- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -nonanoic acid, and
3- (6-Methoxypyridin-3-yl) -3- {2-oxo-3- [3- (5,6,7,8-tetrahydro- [1,8] -naphthyridin-2-yl) -propyl ] -Imidazolidin-1-yl} -propionic acid,
26. Use according to claim 25, or alternatively selected from the group consisting of pharmaceutically acceptable salts thereof.
3−フェニル−4−(4−(メチルスルホニル)フェニル)−2−(5H)−フラノン、
4−[5−(4−メチルフェニル)−3−(トリフルオロメチル)−1H−ピラゾール−1−イル]ベンゼンスルホンアミド、
4−(5−メチル−3−フェニル−4−イソオキサゾリル)−ベンゼンスルホンアミド、
N−[[4−(5−メチル−3−フェニル−4−イソオキサゾリル)フェニル]スルホニル]プロパンアミド、
5−クロロ−3−(4−(メチルスルホニル)フェニル)−2−(2−メチル−5−ピリジニル)ピリジン、及び、
(5S)−5−エチル−5−メチル−4−(4−(メタンスルホニル)フェニル)−3−(2−プロポキシ)−(5H)−フラン−2−オン、
または、医薬的に許容されるそれらの塩からなるグループから選択される、請求項25に記載の使用。 A COX-2 inhibitor
3-phenyl-4- (4- (methylsulfonyl) phenyl) -2- (5H) -furanone,
4- [5- (4-methylphenyl) -3- (trifluoromethyl) -1H-pyrazol-1-yl] benzenesulfonamide,
4- (5-methyl-3-phenyl-4-isoxazolyl) -benzenesulfonamide,
N-[[4- (5-Methyl-3-phenyl-4-isoxazolyl) phenyl] sulfonyl] propanamide,
5-chloro-3- (4- (methylsulfonyl) phenyl) -2- (2-methyl-5-pyridinyl) pyridine, and
(5S) -5-ethyl-5-methyl-4- (4- (methanesulfonyl) phenyl) -3- (2-propoxy)-(5H) -furan-2-one,
26. Use according to claim 25, or alternatively selected from the group consisting of pharmaceutically acceptable salts thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25944101P | 2001-01-03 | 2001-01-03 | |
PCT/US2001/049638 WO2002053099A2 (en) | 2001-01-03 | 2001-12-28 | Methods and compositions for treating periodontal disease |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004517853A JP2004517853A (en) | 2004-06-17 |
JP2004517853A5 true JP2004517853A5 (en) | 2005-12-22 |
Family
ID=22984959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002554050A Withdrawn JP2004517853A (en) | 2001-01-03 | 2001-12-28 | Method and composition for treating periodontal disease |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1349548A4 (en) |
JP (1) | JP2004517853A (en) |
AU (1) | AU2002246757B2 (en) |
CA (1) | CA2432504A1 (en) |
WO (1) | WO2002053099A2 (en) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
PT3050878T (en) | 2013-09-24 | 2021-12-02 | Fujifilm Corp | Novel nitrogen-containing compound or salt thereof, or metal complex thereof |
GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5190981A (en) * | 1989-08-17 | 1993-03-02 | Sepracor Inc. | Formulation containing S(+) enantiomer of flurbiprofen or ketoprofen and method of use for oral administration for prevention and treatment of bone loss associated with periodontal disease |
US20020028798A1 (en) * | 1995-12-12 | 2002-03-07 | Omeros Medical Systems | Irrigation solution and method for inhibition of pain and inflammation |
US6048861A (en) * | 1997-12-17 | 2000-04-11 | Merck & Co., Inc. | Integrin receptor antagonists |
US6017926A (en) * | 1997-12-17 | 2000-01-25 | Merck & Co., Inc. | Integrin receptor antagonists |
PL341095A1 (en) * | 1997-12-17 | 2001-03-26 | Merck & Co Inc | Compounds acting as antagonists of integrin receptor |
US6136804A (en) * | 1998-03-13 | 2000-10-24 | Merck & Co., Inc. | Combination therapy for treating, preventing, or reducing the risks associated with acute coronary ischemic syndrome and related conditions |
EP1100506A4 (en) * | 1998-07-29 | 2002-06-26 | Merck & Co Inc | Integrin receptor antagonists |
BR0011108A (en) * | 1999-06-02 | 2002-03-19 | Merck & Co Inc | Compound, pharmaceutical composition, and processes of eliciting an integrin receptor antagonizing effect, treating or preventing osteoporosis, treating or preventing a condition mediated by antagonism of an integrin receptor, inhibiting bone resorption in a mammal in need for it, and treatment of tumor development |
-
2001
- 2001-12-28 EP EP01994350A patent/EP1349548A4/en not_active Ceased
- 2001-12-28 AU AU2002246757A patent/AU2002246757B2/en not_active Ceased
- 2001-12-28 JP JP2002554050A patent/JP2004517853A/en not_active Withdrawn
- 2001-12-28 WO PCT/US2001/049638 patent/WO2002053099A2/en active IP Right Grant
- 2001-12-28 CA CA002432504A patent/CA2432504A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2014372166B2 (en) | Pharmaceutical combinations | |
US20140011798A1 (en) | Imidazopyrrolidinone compounds | |
JP2018511626A5 (en) | ||
JP2018535999A5 (en) | ||
CA2345641A1 (en) | A method for treating inflammatory diseases by administering a thrombin inhibitor | |
JP2007519649A5 (en) | ||
RU2011108026A (en) | TUBERCULOSIS COMBINED THERAPY | |
JP2006503866A (en) | Synergistic methods and compositions for treating cancer | |
JP2015517566A5 (en) | ||
JP2020516671A5 (en) | ||
JP2013531070A5 (en) | ||
EA034872B1 (en) | Combination of a mek inhibitor cobimetinib and an erk inhibitor (s)-1-(1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1h-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1h)-one for use in treatment of cancer diseases | |
JP2009501775A5 (en) | ||
RU2003112610A (en) | Pyrazole derivatives for the treatment of virx diseases | |
RU2003103780A (en) | COMPOUNDS OF Phenylpyridazine AND THEIR MEDICINES CONTAINING THEM | |
JP2005520797A5 (en) | ||
JP2012517441A5 (en) | ||
WO2005074930A1 (en) | Pharmaceutical combinations of (s) -pantoprazole with nsaid or corticosteroids | |
JP2004517853A5 (en) | ||
AU2001259974A1 (en) | Combination therapy using cox-2 selective inhibitor and thromboxane inhibitor and compositions therefor | |
JP2004524279A5 (en) | ||
JP2006516626A5 (en) | ||
NL1024816C2 (en) | Adhesive-coated sheet for dermal delivery of a selective cyclooxygenase-2 inhibitor. | |
EP1251839A2 (en) | Use of cox-2 inhibitors for the treatment of constipation | |
EP1390026B1 (en) | Treatment of hpv caused diseases |